Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

85 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Atea Pharmaceuticals : Absorption, Distribution, Metabolism, and Excretion of Bemnifosbuvir in Rats (SAT 411)
PU
Transcript : Atea Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
Transcript : Atea Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Transcript : Atea Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Transcript : Atea Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Transcript : Atea Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Transcript : Atea Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 08, 2023
Atea Pharmaceuticals : Low Risk of Drug-Drug Interactions (DDIs) for Bemnifosbuvir (BEM) Based Upon In Vitro Metabolism and Transporter Interaction Studies
PU
Transcript : Atea Pharmaceuticals, Inc., Q4 2022 Earnings Call, Feb 28, 2023
Transcript : Atea Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 03:00 PM
Transcript : Atea Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 07, 2022
Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 12:55 PM
Transcript : Atea Pharmaceuticals, Inc. - Special Call
Atea Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
Transcript : Atea Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 08, 2022
Kezar Life Sciences, Inc. Announces Executive Changes
CI
Transcript : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
Atea Pharmaceuticals : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update - Form 8-K
PU
Transcript : Atea Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 28, 2022
Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
GL
Transcript : Atea Pharmaceuticals, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 08:15 AM
Atea Pharmaceuticals Highlights Strategic Priorities for 2022
GL
Atea Pharmaceuticals Highlights Strategic Priorities for 2022
GL
Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
GL
Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
GL
Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19
GL
Kezar Appoints Courtney Wallace to its Board of Directors
BU
Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
GL
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
GL
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results - Form 8-K
PU
Transcript : Atea Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 11, 2021
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
GL
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
GL
Transcript : Atea Pharmaceuticals, Inc. - Special Call
Atea's Covid-19 Trial Misses Objective in Overall Patient Population
DJ
Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 02:00 PM
Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
GL
Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses
GL
Transcript : Atea Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 12, 2021
Atea Pharmaceuticals : Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
Atea Pharmaceuticals : Sublease Agreement, dated as of July 19, 2021, by and between the Company and DataRobot, Inc (Form 8-K)
PU
Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
GL
Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis
GL
Kezar Life Sciences : Submission of Matters to a Vote of Security Holders (Form 8-K)
PU
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
GL
Kezar Life Sciences : Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors
BU
Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
GL
Atea Pharmaceuticals : CONSULTING AGREEMENT (Form 8-K)
PU
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors
GL
Transcript : Atea Pharmaceuticals, Inc., Q1 2021 Earnings Call, May 13, 2021
No results for this search
  1. Stock Market
  2. Advanced search
  3. Jean-Pierre Sommadossi
  4. News